MFNG: A Potential Drug Target for Mental Health (G4242)

Target Name: MFNG

NCBI ID: G4242

MFNG

Other Name(s): Beta-1,3-N-acetylglucosaminyltransferase manic fringe (isoform 1) | MFNG_HUMAN | O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase | OTTHUMP00000043697 | OTTHUMP00000043700 | O-fucosylpeptide beta-1,3-N-acetylglucosaminyltransferase | MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase, transcript variant 1 | O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase (Manic fringe) | Beta-1,3-N-acetylglucosaminyltransferase manic fringe | OTTHUMP00000043698 | MFNG variant 1 | Manic fringe homolog | MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase

MFNG: A Potential Drug Target for Mental Health

MFNG, or Beta-1,3-N-acetylglucosaminyltransferase manic fringe (ISOFORM 1), is a gene that has been identified as a potential drug target in the field of mental health. MFNG is a protein that is expressed in the front of the brain and is involved in the production of the neurotransmitter serotonin.

Research has shown that MFNG is involved in the regulation of serotonin levels in the brain and that disruptions in this pathway have been linked to a variety of mental health conditions, including depression, anxiety, and schizophrenia.

One of the key ways in which MFNG is thought to be involved in the regulation of serotonin levels is through its role in the production of the neurotransmitter melatonin. Melatonin is a hormone that is produced by the pineal gland in order to help regulate sleep-wake cycles and improve the quality of sleep.

Research has shown that MFNG is involved in the production of melatonin and that disruptions in this pathway can contribute to the development of insomnia and other sleep disorders. Additionally, MFNG has been shown to play a role in the regulation of other neurotransmitters, including dopamine and GABA.

Another way in which MFNG is thought to be involved in the regulation of serotonin levels is through its role in the production of the neurotransmitter norepinephrine. Norepinephrine is a hormone that is involved in the regulation of heart rate and blood pressure, and is thought to play a key role in the development of anxiety and depression.

Research has shown that MFNG is involved in the production of norepinephrine and that disruptions in this pathway can contribute to the development of these conditions. Additionally, MFNG has been shown to play a role in the regulation of other neurotransmitters, including dopamine and GABA.

In conclusion, MFNG is a gene that is involved in the regulation of serotonin levels in the brain. Disruptions in this pathway have been linked to a variety of mental health conditions, including depression, anxiety, and schizophrenia. As such, MFNG may be a promising drug target for the treatment of these conditions. Further research is needed to fully understand the role of MFNG in the regulation of serotonin levels and to develop safe and effective treatments.

Protein Name: MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase

Functions: Glycosyltransferase that initiates the elongation of O-linked fucose residues attached to EGF-like repeats in the extracellular domain of Notch molecules (PubMed:10935626). Modulates NOTCH1 activity by modifying O-fucose residues at specific EGF-like domains resulting in inhibition of NOTCH1 activation by JAG1 and enhancement of NOTCH1 activation by DLL1 via an increase in its binding to DLL1 (By similarity)

The "MFNG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MFNG comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets